ECHOIQ LIMITED (EIQ)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EIQ

EIQ - ECHOIQ LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Software & Services
Debt/EBITDA: -0
Index: ALL-ORDS | ALL-TECH

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.615

25 Jun
2026

0.375

OPEN

$1.75

30.24%

HIGH

$1.88

17,843,376

LOW

$1.53

TARGET
$1.583

+0.18 change from previous day

 -2.0% downside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
EIQ: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 2.3 - 1.0 xxx
DPS (cps) xxx 0.0 N/A xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-2.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.1 M
Book Value Per Share xxxxxxxxxxxxxxx3.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-6.5 M
Net Profit Margin xxxxxxxxxxxxxxx-13,078.24 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-89.84 %
Return on Invested Capital xxxxxxxxxxxxxxx-89.84 %
Return on Assets xxxxxxxxxxxxxxx-83.87 %
Return on Equity xxxxxxxxxxxxxxx-89.84 %
Return on Total Capital xxxxxxxxxxxxxxx-100.53 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-6.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx7 M
Price To Book Value xxxxxxxxxxxxxxx6.24

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx35.30 %
Cost of Goods Sold xxxxxxxxxxxxxxx1 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx14 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

26/06/2026

1

Initiation of coverage with Speculative Buy

$1.65

2.17%

Bell Potter initiates coverage of EchoIQ with a Speculative Buy rating and $1.65 target. First off among catalysts is the pending approval of the 510(K) submission for  EchoSolv HF, focused on left ventricle disease and this is expected in the next month or so.

If approved, the broker points out the product is likely to attract keen interest from cardiology buyers around  the world and will be adopted by the Mayo Clinic.

The AI-driven software is used to analyse echocardiographic data and aid clinicians in diagnosing serious cardiac disease including aortic stenosis and left ventricle dysfunction.

FORECAST
Bell Potter forecasts a full year FY26 EPS of minus -1.60 cents.
Bell Potter forecasts a full year FY27 EPS of minus -1.50 cents.

Morgans

xx/xx/xxxx

1

xxxxxxxxxx xx xxxxxxxx xxxx xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Shaw and Partners

22/06/2026

1

Buy

$1.50

-7.12%

Shaw and Partners retains a Buy rating for EchoIQ with a $1.50 target price following proposed rule adjustments by the US Centers for Medicare and Medicaid Services regarding transcatheter aortic valve replacement coverage.

Commentary suggests the planned regulatory expansion to include certain asymptomatic patients will drive increased echocardiography volumes in a heavily underdiagnosed market.

The analyst notes this policy shift could accelerate clinical demand for the company's EchoSolv AS platform, lifting its total addressable aortic stenosis market by roughly 40% to US$1.26bn.

Commercial deployment remains on track within the Mount Sinai Health System following initial FDA clearance protocols.

Standing financial year forecasts remain unadjusted ahead of a final regulatory insurance coverage decision scheduled for mid-September 2026.

FORECAST
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -2.10 cents.
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -1.40 cents.
Access Extra Coverage Research History >

EIQ STOCK CHART

FNArena News on EIQ

Latest Medical Equipment & Devices News

1
Shortages Chip Away At ResMed’s Big Break

Mar 30 2022 - Australia
2
Opportunity for Fisher & Paykel Healthcare

Mar 25 2022 - Australia
3
Distribution Anxiety For Nanosonics

Feb 10 2022 - Australia
4
Brokers Awake To ResMed’s Potential

Jan 31 2022 - Australia
5
Covid Benefits F&P Healthcare, For Now

Dec 06 2021 - Australia
6
Will Shortages Limit Upside For ResMed?

Nov 01 2021 - Australia
7
Nanosonics Unveils Its New Product

Aug 26 2021 - Australia
8
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals
9
Breakout For Cochlear

Aug 10 2021 - Technicals
10
Will ResMed’s Market Share Gains Last?

Aug 09 2021 - Australia